Lyell Immunopharma, Inc share price logo

Lyell Immunopharma, Inc Share Price

NASDAQ: LYEL

Small Cap

$19.61

+0.06

(+0.31%)

as on

Lyell Immunopharma, Inc Stock Performance

as on March 25, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $18.73
    $19.89
    downward going graph

    4.49%

    Downside

    1.43%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $7.65
    $45.00
    downward going graph

    60.99%

    Downside

    129.47%

    Upside

    downward going graph

Lyell Immunopharma, Inc share price movements today

Previous Close
$19.55
Open
$19.32
Volume
195.0K
Day's Low - High
$18.73 - $19.89
52 Week Low - High
$7.65 - $45.00

Lyell Immunopharma, Inc Historical Returns

1 Month Return
-16.74 %
3 Month Return
-49.35 %
1 Year Return
+ 86.12 %
3 Year Return
-51.37 %
5 Year Return
0 %

Lyell Immunopharma, Inc Stock Fundamentals & Key Indicators

Check Lyell Immunopharma, Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$445.6M

EPS (TTM)

-8.7167

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

-1.78

Industry PE ratio

-4.738881355932204

PEG Ratio

0

EBITDA

-186.7M

Revenue (TTM)

36.0K

Profit Margin

0.00%

Return On Equity TTM

-86.99%

Lyell Immunopharma, Inc Stock Valuation

Track how Lyell Immunopharma, Inc P/E has moved over time to understand its valuation trends.

Lyell Immunopharma, Inc in the last 5 years

  • Overview

  • Trends

Lowest (-132.44x)

December 31, 2022

Industry (-4.74x)

March 25, 2026

Today (-1.78x)

March 25, 2026

Highest (-1.74x)

December 31, 2025

LowHigh

Today’s Price to Earnings Ratio: -1.78x

Lyell Immunopharma, Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Lyell Immunopharma, Inc with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Lyell Immunopharma, Inc image
Lyell Immunopharma, Inc
BUY$445.6MNA-1.780.00%
Alnylam Pharmaceuticals, Inc. image
Alnylam Pharmaceuticals, Inc.
BUY$41.4B126.75%133.418.45%
Vertex Pharmaceuticals Incorporated image
Vertex Pharmaceuticals Incorporated
BUY$115.3B112.49%29.6832.94%
Beone Medicines Ltd image
Beone Medicines Ltd
NA$31.6BNA1115.37%
Regeneron Pharmaceuticals, Inc. image
Regeneron Pharmaceuticals, Inc.
BUY$77.5B58.91%17.6731.41%

Stock Returns calculator for Lyell Immunopharma, Inc Stock including INR - Dollar returns

The Lyell Immunopharma, Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

Lyell Immunopharma, Inc investment value today

Current value as on today

₹1,96,303

Returns

₹96,303

(+96.3%)

Returns from Lyell Immunopharma, Inc Stock

₹86,762 (+86.76%)

Dollar Returns*

₹9,541 (+9.54%)

Analyst Recommendation on Lyell Immunopharma, Inc Stock

Based on 10 analysts

BUY

70.00%

Buy

30.00%

Hold

0.00%

Sell

Based on 10 analysts, 70% of analysts recommend a 'BUY' rating for Lyell Immunopharma, Inc. Average target price of $32.5

Lyell Immunopharma, Inc Share Price Target

Get share price movements and forecasts by analysts on Lyell Immunopharma, Inc.

What analysts predicted

39.66%UPSIDE

Target Price

$32.5

Current Price

$19.61

Analyzed by

10 Analysts

Target

$32.50

Lyell Immunopharma, Inc target price $32.5, a slight upside of 39.66% compared to current price of $19.61. According to 10 analysts rating.

Lyell Immunopharma, Inc Stock’s Investor Sentiment and Interest

Search interest for Lyell Immunopharma, Inc Stock has decreased by -3% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-3% versus previous 30 day period

Lyell Immunopharma, Inc Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Total Revenue
0
0
0
0
0
0
0
0
0
0
Gross Profit
-5
-5
0
0
0
0
0
0
0
-2
Operating Income
-60
-59
-55
-51
-50
-201
-57
-47
-37
-62
EBITDA
-45
-47
-50
-46
-45
-57
-53
-42
-36
-59
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
5
5
5
4
4
5
3
3
2
2
Income Before Tax
-50
-52
-60
-45
-44
-191
-52
-42
-38
-140
Income Tax Expense
-6
5
4
-
-
-
-
-
-
-
Net Income
-50
-52
-60
-45
-44
-191
-52
-42
-38
-140
Net Profit Margin
-203412.00%
-407153.85%
-2022233.33%
-352376.92%
-131126.47%
-1744863.64%
-745642.86%
-533550.00%
-258973.33%
-2345383.33%

Lyell Immunopharma, Inc Annual Profit & Loss

All numbers in Millions USD

Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
0
7
10
84
0
0
0
Gross Profit
0
7
10
84
0
0
-11
Operating Income
-102
-211
-214
-187
-247
-358
-203
EBITDA
-100
-215
-201
-169
-226
-200
-192
Interest Expense
-
5
1
-
-
-
-
Depreciation
1
4
13
18
20
19
11
Income Before Tax
-129
-204
-250
-183
-234
-342
-274
Income Tax Expense
-8
-5
35
-178
-10
-
-
Net Income
-129
-204
-250
-183
-234
-342
-274
Net Profit Margin
-19692.09%
-2636.31%
-2349.47%
-216.24%
-180486.15%
-562285.25%
-762355.56%

Lyell Immunopharma, Inc Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
-52
-60
-45
-44
-191
-52
-42
-38
-140
Operating Cash Flow
-40
-42
-38
-35
-47
-54
-34
-28
-32
Investing Cash Flow
-100
21
45
1
53
69
12
3
-31
Financing Cash Flow
0
0
0
-
0
0
0
50
0
Change in Cash
-140
-19
7
-33
5
14
-21
24
-63

Lyell Immunopharma, Inc Annual Cash Flow

All numbers in Millions USD

Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-204
-250
-183
-234
-342
-274
Operating Cash Flow
-160
-126
-169
-163
-162
-150
Investing Cash Flow
-273
-121
-11
184
122
54
Financing Cash Flow
476
401
10
1
1
50
Change in Cash
42
153
-170
22
-38
-45

Global Institutional Holdings in Lyell Immunopharma, Inc

Funds
Holdings
ARCH VENTURE CORP
12.98%
MWG Management Ltd.
4.74%
Foresite Capital Management V, LLC
2.25%
Foresite Capital Management V, LLC
2.24%
Takeda Pharmaceutical Co Ltd
0.21%
See all

Insights on Lyell Immunopharma, Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, LYEL has outperformed top 5 stocks with highest market-cap in its industry

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Lyell Immunopharma, Inc has experienced a drawdown of -51.4%, however Alnylam Pharmaceuticals, Inc. resisted the overall trend and outperformed by 41.2%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 3 months, LYEL stock has moved down by -49.4%

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 15.0K → 6.0K (in $), with an average decrease of 60.0% per quarter

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, -38.84M → -140.72M (in $), with an average decrease of 262.3% per quarter

About Lyell Immunopharma, Inc

we are entering a new era of medicine, where cancer is treated with cellular therapies: living, smart, targeted drugs. while enormous strides have been made, especially in hematologic cancers, the full promise of these therapies still lies ahead. cell-based immunotherapies have yet to show substantial benefit in solid tumors, which represent the vast majority of cancers. our goal is nothing less than to develop curative cell-based immunotherapies for any cancer, with a focus on car-ts and solid tumors.
OrganisationLyell Immunopharma, Inc
Headquarters201 Haskins Way, South San Francisco, CA, United States, 94080
IndustryServices
CEODr. Lynn Seely M.D., Ph.D.
E-voting on sharesClick here to vote

Key Management of Lyell Immunopharma, Inc

Name

Title

Dr. Lynn Seely M.D., Ph.D.

Principal Executive Officer, President, CEO & Director

Ms. Smital Shah M.B.A.

Principal Financial Officer, CFO & Chief Business Officer

Nellie Dillery

Director of Accounting

Ms. Ann Tomlin

Chief Human Resources Officer

Dr. Richard D. Klausner M.D.

Founder & Executive Chairman

Mr. Stephen J. Hill

Chief Operating Officer

Prof. Stanley R. Riddell M.D.

Founder & Scientific Advisor

Dr. Crystal L. Mackall M.D.

Founder & Scientific Advisor

Dr. Gary K. Lee Ph.D.

Chief Scientific Officer

Mr. Mark A. Meltz J.D.

General Counsel & Corporate Secretary

FAQs

What is Lyell Immunopharma, Inc share price today?

Lyell Immunopharma, Inc share price today is $19.61 as on at the close of the market. Lyell Immunopharma, Inc share today touched a day high of $19.89 and a low of $18.73.

What is the 52 week high and 52 week low for Lyell Immunopharma, Inc share?

Lyell Immunopharma, Inc share touched a 52 week high of $45 on and a 52 week low of $7.65 on . Lyell Immunopharma, Inc stock price today i.e. is closed at $19.61,which is 56.42% down from its 52 week high and 156.34% up from its 52 week low.

What is Lyell Immunopharma, Inc's market capitalisation today?

Lyell Immunopharma, Inc market capitalisation is $0.00T as on .

How to invest in Lyell Immunopharma, Inc Stock (LYEL) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Lyell Immunopharma, Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Lyell Immunopharma, Inc Shares that will get you 0.0765 shares as per Lyell Immunopharma, Inc share price of $19.61 per share as on March 25, 2026 at 1:29 am IST.

What is the minimum amount required to buy Lyell Immunopharma, Inc Stock (LYEL) from India?

Indian investors can start investing in Lyell Immunopharma, Inc (LYEL) shares with as little as ₹93.734 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹937.34 in Lyell Immunopharma, Inc stock (as per the Rupee-Dollar exchange rate as on ). Based on Lyell Immunopharma, Inc share’s latest price of $19.61 as on March 25, 2026 at 1:29 am IST, you will get 0.5099 shares of Lyell Immunopharma, Inc. Learn more about fractional shares .